NCT01321437View on ClinicalTrials.gov

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
MelanomaMalignant MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC Melanoma
Interventions
PROCEDURE

therapeutic conventional surgery

Undergo surgery

OTHER

laboratory biomarker analysis

Correlative studies

DRUG

Axitinib

Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center, Orange

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of California, Irvine

OTHER

NCT01321437 - Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | Biotech Hunter | Biotech Hunter